Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Changing The EU Public Health Dynamic: Better Science, Regulation And Access Policies To Deliver Biopharmaceutical Innovation For Europe's Citizens
Better science, better regulation and better access policies are needed in Europe to support an
generic viagra online
President Obama To Visit Ghana Friday
IRIN reports that Ghanaians "are mixing high hopes with caution" in anticipation of President Obama"s arrival in the country Friday - "his first visit to sub-Saharan Africa." Obama is expected to "make a major policy statement," according to IRIN. The article looks back at some of the commitments that former Presidents Bush and Clinton previously made to Africa (7/8).
News of the day
NCDP Health Care Reform Recommendations Advocate For Diabetes Prevention, Treatment And Care
The National Changing Diabetes((R)) Program (NCDP), a program of Novo Nordisk, and several member associations today urged President Obama and members of Congress to make the prevention, detection and treatment of diabetes, one of the nation"s most pervasive and costly diseases, a priority in reforming the U.S. healthcare system.
Health Insurance

Phase II Study Of Sunitinib In Men With Advanced Prostate Cancer

UroToday.com - In the Annals of Oncology, Dr. Dror Michaelson and associates reported Phase II data on the efficacy and safety of the tyrosine kinase inhibitor sunitinib in patients with castration-resistant prostate cancer (CRPC). Sunitinib inhibits vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), both elevated in prostate cancer (CaP). Two groups of patients were studied; group A, which was chemotherapy naç¯ve and group B, which had failed docetaxel. The primary endpoint was PSA decline >50% from baseline. Secondary endpoints included objective response rate, safety, tolerability and serum biomarkers. Treatment was in 6-week cycles, consisting of 50mg daily for 4 weeks followed by 2 weeks off. Concurrent treatment with bisphosphonates was permitted. Seventeen men in each group had data available for analysis. Only one patient in group A, and one patient in group B demonstrated a >50% PSA decline. Fourteen of 34 men had some PSA decline and 8 men (34%) had a >30% PSA decline. At 12-week analysis it was noted that radiographic improvements were present in some patients who nevertheless had increasing PSA levels. Based upon not having 2 or more PSA response criteria met, the study enrollment was not continued. Adverse events were primarily grade 1 or 2 and included nausea, fatigue, anorexia, taste disturbance, vomiting, diarrhea and skin rash. Regarding biomarkers, sVEGFR2, PDGFaa, and leptin all decreased but did not correlate with PSA. Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, Spicer B, Gurski C, Kantoff PW, Smith MR Ann Oncol. 2009 May;20(5):913-20. doi:10.1093/annonc/mdp111 Written by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009